CLASStime: Cannabis-based medicines

+Class
In print
summer hiatus

CLASStime: Cannabis-based medicines

Guest Writer

Guest Writer

CLASS Cannabis

We are on our summer break and the editorial office is closed until 17 January. In the meantime, please enjoy our Summer Hiatus series, an eclectic mix from our news and clinical archives and articles from The Conversation throughout the year

For the last decade, Martin Woodbridge has worked with regulators, and industry and health professionals to promote the rational use of cannabis-based medicines. Here, he considers the introduction of cannabis-based medicines to New Zealand and explores what it means for pharmacy practice

Our suite of CLASS activities provides meaningful independent and peer group learning that you can put into action, while helping you complete your an
References

1. Ministry of Health. Medicinal Cannabis Agency - Minimum quality standard. 1 October 2021. tinyurl.com/MOHMedCannMQS

2. Pharmacology and Therapeutics Advisory Committee. Record of the Pharmacology and Therapeutics Advisory Committee Meeting. 25 March 2021. pharmac.govt.nz/assets/ptacminutes-2021-03.pdf

3. US Food and Drug Administration. What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD. tinyurl.com/FDAMedCannabis